title: Combined aliskiren and amlodipine reduce albuminuria via reduction in renal inflammation in diabetic rats.
abstract: We hypothesized that compared with hydrochlorothiazide (HCTZ), the renin inhibitor aliskiren (ALISK) or amlodipine (AMLO) and their combination reduce albuminuria via reduction in renal inflammation, independent of blood pressure (BP) changes. We studied normal and streptozotocin-induced diabetic (DM) Sprague-Dawley rats treated for 6 weeks with vehicle, ALISK, HCTZ, or AMLO individually and combined and evaluated the effects of treatments on BP, urine albumin to creatinine ratio, renal interstitial fluid levels of angiotensin II, tumor necrosis factor alpha (TNF-α), and interleukin 6 (IL-6) and renal expression of TNF-α, IL-6, transforming growth factor beta 1, and nuclear factor kappa B. There were no differences in BP between treatments. Only ALISK and its combinations reduced renal interstitial fluid angiotensin II. Urine albumin to creatinine ratio increased in DM rats and decreased with ALISK alone or combined with HCTZ or AMLO. HCTZ or AMLO individually and combined did not influence urine albumin to creatinine ratio. Renal interstitial fluid TNF-α and IL-6, and the renal expression of TNF-α, IL-6, transforming growth factor beta 1, and nuclear factor kappa B were increased in DM rats. These renal inflammatory markers were reduced only with ALISK or AMLO individually or combined with other treatments. We conclude that ALISK alone and combined with HCTZ or AMLO reduced albuminuria in diabetes via reduction in renal inflammation, independent of BP changes.
authors.affiliation: Department of Medicine, University of Virginia Health System, Charlottesville, VA 22908-1409, USA.
authors.forename: Luis C
authors.initials: LC
authors.lastname: Matavelli
authors.forename: Jiqian
authors.initials: J
authors.lastname: Huang
authors.forename: Helmy M
authors.initials: HM
authors.lastname: Siragy
mesh_terms: D000419:Albuminuria / Q000188:drug therapy*; D000577:Amides / Q000008:administration & dosage / Q000494:pharmacology*; D017311:Amlodipine / Q000008:administration & dosage / Q000494:pharmacology*; D000818:Animals; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000494:pharmacology; D001794:Blood Pressure / Q000187:drug effects; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy / Q000503:physiopathology; D004359:Drug Therapy, Combination; D005650:Fumarates / Q000008:administration & dosage / Q000494:pharmacology*; D006852:Hydrochlorothiazide / Q000008:administration & dosage / Q000494:pharmacology*; D007249:Inflammation / Q000188:drug therapy / Q000503:physiopathology; D007668:Kidney; D008297:Male; D051381:Rats; D017207:Rats, Sprague-Dawley; D013311:Streptozocin; D000092502:Renin Inhibitors
chemical_list: D000577:Amides; D017311:Amlodipine; D000959:Antihypertensive Agents; D005650:Fumarates; D006852:Hydrochlorothiazide; D013311:Streptozocin; D000092502:Renin Inhibitors; C446481:aliskiren
references.citation: Kidney Int. 2008 Jun;73(12):1419-25
references.pmid: 18337712
references.citation: Trends Endocrinol Metab. 2003 Aug;14(6):274-81
references.pmid: 12890592
references.citation: J Clin Invest. 1997 Jul 15;100(2):264-9
references.pmid: 9218502
references.citation: Ann N Y Acad Sci. 2006 Nov;1084:89-117
references.pmid: 17151295
references.citation: Lancet. 2011 Jan 22;377(9762):312-20
references.pmid: 21236483
references.citation: Hypertension. 2003 Dec;42(6):1206-52
references.pmid: 14656957
references.citation: Circulation. 2005 Mar 1;111(8):1012-8
references.pmid: 15723979
references.citation: Diabetologia. 2007 Nov;50(11):2398-404
references.pmid: 17828524
references.citation: Clin Exp Pharmacol Physiol. 2010 Mar;37(3):277-82
references.pmid: 19769609
references.citation: Am J Kidney Dis. 2007 Feb;49(2 Suppl 2):S12-154
references.pmid: 17276798
references.citation: Biochem Biophys Res Commun. 2003 Sep 5;308(4):698-705
references.pmid: 12927775
references.citation: Endocrinology. 2003 Jun;144(6):2229-33
references.pmid: 12746279
references.citation: Circ Res. 1999 Apr 2;84(6):695-703
references.pmid: 10189357
references.citation: Hypertension. 2005 Sep;46(3):569-76
references.pmid: 16103264
references.citation: Am J Physiol Heart Circ Physiol. 2006 Mar;290(3):H923-4
references.pmid: 16467462
references.citation: Exp Physiol. 2008 Jul;93(7):817-24
references.pmid: 18296490
references.citation: Hypertension. 2005 Sep;46(3):584-90
references.pmid: 16043663
references.citation: Hypertension. 2008 Jul;52(1):130-6
references.pmid: 18490518
references.citation: N Engl J Med. 2001 Sep 20;345(12):861-9
references.pmid: 11565518
references.citation: Hypertens Res. 2010 Apr;33(4):279-87
references.pmid: 20203685
references.citation: J Am Soc Nephrol. 2004 Aug;15(8):2139-51
references.pmid: 15284299
references.citation: N Engl J Med. 2008 Jun 5;358(23):2433-46
references.pmid: 18525041
references.citation: Cytokine. 2000 Mar;12(3):294-7
references.pmid: 10704258
references.citation: N Engl J Med. 1993 Nov 11;329(20):1456-62
references.pmid: 8413456
references.citation: Diabetes. 2006 May;55(5):1252-9
references.pmid: 16644679
references.citation: J Cardiovasc Pharmacol. 2006 May;47(5):636-42
references.pmid: 16775501
references.citation: J Am Soc Nephrol. 2008 Mar;19(3):433-42
references.pmid: 18256353
references.citation: Circulation. 2009 Jan 27;119(3):417-25
references.pmid: 19139391
references.citation: Jpn J Pharmacol. 2002 Jun;89(2):157-63
references.pmid: 12120758